Egypt Cardiovascular Drugs Market Analysis Report 2022 to 2030

Egypt Cardiovascular Drugs Market Analysis

$ 3999

Egypt Cardiovascular Drug Market is at around $0.4 Bn in 2022 and is projected to reach $0.6 Bn in 2030, exhibiting a CAGR of 5.3% during the forecast period. The market is expanding as a result of government initiatives, increased access to health insurance, and a rise in cardiovascular load. The market is dominated by key players like Copad Pharma, Menarini Pharmaceutical, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., F. Hoffman-La Roche, Pfizer Inc., Astra Zeneca, Sanofi, Novartis, and GSK.

ID: IN10EGPH007 CATEGORY: Pharmaceuticals GEOGRAPHY: Egypt AUTHOR: Aneri Parekh

Buy Now

Egypt Cardiovascular Drug Market Executive Summary

Egypt Cardiovascular Drug Market is at around $0.4 Bn in 2022 and is projected to reach $0.6 Bn in 2030, exhibiting a CAGR of 5.3% during the forecast period.

Conditions affecting the heart and blood vessels together are called cardiovascular diseases. It’s not a single illness; rather, it refers to a collection of problems that may affect the body’s ability to circulate blood and the function of the heart. Cardiovascular diseases encompass a range of conditions, including peripheral artery disease, coronary heart disease, rheumatic heart disease, heart failure, and cerebrovascular disease. Medication used to treat the disorders includes beta blockers, ACE inhibitors, PCSK9 inhibitors, calcium channel blockers, and antiarrhythmics.

The market for cardiovascular drugs in Egypt is continuing to grow due to the rising incidence of cardiovascular illnesses. The overall optimistic outlook for Egypt's cardiovascular pharmaceutical industry is a result of government initiatives and growing healthcare awareness.

Over the last 20 years, pharmaceutical revenue grew dramatically, reaching $138.33 Bn worldwide in 2022. With the introduction of new technologies and more economical and effective manufacturing techniques, the pharmaceutical industry has undergone a significant transformation. The market's expansion has also been facilitated by the growing amount of capital flowing into this sector.

Despite COVID-19-related logistical and production difficulties, Boehringer Ingelheim's pharmaceutical revenue increased by 6% to $17 Bn in 2021. The company researches diseases like cardiovascular disorders and immunology. Its primary focus is on creating new medications, treatments, and methods for treating, diagnosing, and preventing chronic diseases.

Egypt cardiovascular drug market

Market Dynamics

Market Growth Drivers:

Growing Prevalence of Cardiovascular Diseases: In Egypt, fatalities from coronary heart disease accounted for 0.17 Mn, or 32.40% of all deaths. The age-adjusted Death Rate is 268.11 per 100,000.

Government Initiatives: A major factor contributing to the expansion of the market in Egypt is the government's emphasis on enhancing the country's healthcare system and raising public awareness of cardiovascular illnesses.

Access to Health Insurance: Government programs to build health infrastructure and provide universal health insurance are making cardiovascular care more accessible, particularly in rural areas.

Market Restraints:

Regulatory Difficulties and Drug Pricing: New and cutting-edge cardiovascular drugs may not be able to reach the market due to convoluted and bureaucratic drug registration and approval procedures.

Drug Counterfeiting and Quality Issues: The availability of low-quality and fake cardiovascular medications in the market puts consumers' health at serious risk and erodes consumer confidence.

Healthcare Policies and Regulatory Landscape

The Egyptian Ministry of Health (MOH)'s pharmaceutical regulatory organization, the Egyptian Drug Authority (EDA), is in charge of ensuring the safety and quality of pharmaceutical products to protect public health. To legally market pharmaceutical products in Egypt, applicants must submit sufficient data from each section proving the product's safety and efficacy for the purposes specified in the suggested labeling to the Egyptian Drug Authority. Applicants might get caught in bureaucracy and uncertainty due to the complex network of paperwork, departments, and procedures involved. Often, navigating this bureaucratic maze requires the knowledge and experience of local experts who are acquainted with the quirks and procedures of the country.

Competitive Landscape

Key Players:

Copad Pharma
Menarini Pharmaceutical
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co.
F. Hoffman-La Roche
Pfizer Inc.
Astra Zeneca
Sanofi
Novartis
GSK

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Egypt Cardiovascular Drug Market Segmentation

By Drug Type

Cephalosporins
Antihypertensive
Antihyperlipidemic
Anticoagulants
Antiplatelet Drug
Others

By Disease Indication

Hypertension
Hyperlipidemia
Coronary Artery Disease
Arrhythmia
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.